Systemic Lupus Erythematosus With or Without Clinical Activity
Conditions
Brief summary
Lupus disease is characterized by the production of pathogenic autoantibodies, which participate in end-organ damages. The phenotype of B cells producing the pathogenic autoantibodies in lupus patients is today unknown. Antinucleosome antibodies are characteristic of lupus disease.This project proposes to detect antinucleosome B cells in lupus patients and to analyse their phenotype and their frequency.
Interventions
Sponsors
University Hospital, Strasbourg, France
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
for SLE patients: SLE patient : diagnostic based on ACR criteria * SLE patient producing seric anti-nucleosome antibodies (ELISA) * SLEDAI-2K activity score : inferior to 5 for quiescent patients, superior to 8 since at least 2 months for active patients
Exclusion criteria
for SLE patients: \-- Other autoimmune diseases than SLE- Induced lupus * Treatment with corticosteroids \>10mg/d (prednisone) for quiescent patients * Treatment with corticosteroids \>20mg/d (prednisone) for active patients * Oral immunosuppressive treatment during the last 6 months (methotrexate, azathioprine, ciclosporine, mycophénolate mofétil) for all patients, treatment during the last year with cyclophosphamide or monoclonal antibodies (rituximab, belimumab) for pour quiescent patients * Disease which can modify B and T lymphocyte functions: primary immune deficiencies, evolutive infections, chronic viral infection (VIH in particular), chemotherapy or neoplasm antecedent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| all cause mortality | 1 year |
Countries
France
Outcome results
None listed